Merck (MRK) Change in Receivables (2009)
Merck's (MRK) quarterly Change in Receivables came in at $14.0 million in Q4 2009, down 88.71% quarter-over-quarter from $124.0 million in Q3 2009.
Powered by 
Analysis
Merck (MRK) Change in Receivables (2009) Analysis & Trends
Merck (MRK) has reported Change in Receivables for 1 consecutive years, with $14.0 million the latest figure, recorded in Q4 2009.
- On a quarterly basis, Change in Receivables changed N/A year-over-year to $14.0 million in Q4 2009; TTM through Dec 2009 was $1.4 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 346.72% from the prior year.
- Change in Receivables was $14.0 million for Q4 2009 at Merck, down from $124.0 million in the prior quarter.
- Over five years, Change in Receivables peaked at $124.0 million in Q3 2009 and troughed at $14.0 million in Q4 2009.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 1.18 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 117.58 Mn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 73.80 Mn |